Pre-clinical Safety, Efficacy of Chandramrita Rasa and its clinical efficacy in the management of Tamaka Shwasa (Bronchial asthma)

Institute for Post Graduate Teaching and Research in Ayurveda0 个研究点目标入组 62 人开始时间: 待定最近更新: 2022年11月21日

试验速览

暂无简介。

•1.Both the sexes having age between 18 years to 60 years
•2.Mild persistent cases of Bronchial Asthma with day time symptoms 3-6/week and nocturnal symptoms with 3-4/month.
•3.Moderate persistence cases with daytime symptoms daily and nocturnal symptoms with one or more than one week but not more than 2 weeks.

•1.Age more than 60 years and below 18 years.
•2.Mild intermittent, Moderated persistent, severe persistent to severe Asthma.
•3.Dyspnoea resulting from other diseases like left ventricular failure, COPD (like Chronic Bronchitis, Emphysema), upper respiratory tract obstruction, bronchiectasis, cases of tuberculosis, interstitial lung disease/occupational lung disease, tropical pulmonary eosinophilia & allergic bronchopulmonary aspergillosis etc.
•4.Patients having anaemia, pneumonia, tuberculosis, lung cancer, lung abscess and other such complicated conditions.
•5.Patients having diabetes, hypertension, Chronic and Acute renal failure etc. conditions in which urination is markedly diminished or excessive were excluded.
•6.HIV positive cases.
•7.Pregnant/lactating mother.
•8.Patients who need Salbutamol inhaler daily.
•9.Patients having classical symptoms of Maha, Urdha, Chhinna and Kshudra Shwasa.

发起方

Institute for Post Graduate Teaching and Research in Ayurveda